Skip to main content
Top
Published in: Intensive Care Medicine 1/2008

Open Access 01-01-2008 | Correspondence

Recombinant human activated factor VII in postpartum hemorrhagic shock: the dark side

Authors: E. J. W. van Veen, W. E. Monteban-Kooistra, J. H. J. M. Meertens, J. J. M. Ligtenberg, J. E. Tulleken, J. G. Zijlstra

Published in: Intensive Care Medicine | Issue 1/2008

Login to get access

Excerpt

Sir: A 38-year-old woman (gravida 2, para 3) was referred to our hospital because of intractable postpartum hemorrhagic shock. During this gemelli pregnancy she was admitted to the hospital three times for vaginal blood loss. Ultrasonography revealed a hematoma and a placenta close to the cervical ostium. Coagulation and platelets were normal. Because of fetal distress during spontaneous labor at 34 weeks an emergency cesarean section was performed. Vaginal hemorrhage began after abdominal closure. Management consisted of uterotonic drugs, intravenous fluids, red blood cells, and fresh frozen plasma without effect. Supravaginal hysterectomy was deemed necessary. Because of pelvic oozing the abdomen was closed after packing of the pelvis. She was still in hemorrhagic shock. Recombinant human activated factor VIIa (rFVIIa; NovoSeven) was administered twice as a 7.2-mg intravenous bolus at an interval of 120 min, but bleeding continued from almost all orifices. The next day she was referred. Hemodynamic instability persisted, and multiorgan failure developed. Angiography of the pelvic arteries resulted in coiling of three small arteries, but hemostasis was not achieved. On the third day tranexamic acid was added and, after lack of effect, a 9-mg intravenous bolus of rFVIIa (90 μg/kg). Coagulation parameters improved and for several hours the hemoglobin level was stable, but she developed blistering of arms, fingers, and feet with slow capillary refill. Toes, heel, and sole of the right foot became black and cold. On laparotomy packings and 9 l blood and cloths were removed. Afterwards there was no bleeding. The ischemia worsened in a few days and spread to the fore foot (Fig. 1) resulting in amputation of the lower extremity. Necrosis also developed on the dorsal side of the left fore arm. Other acra were cyanotic but did not become necrotic. Since delivery she had received 48 U red blood cells, 30 U fresh frozen plasma and 17 U five donors each of platelets. Multiorgan failure improved, and 19 days after admission the patient was discharged to the ward.
Literature
1.
go back to reference Franchini M, Lippi G, Franchi M (2007) The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage. Br J Obstet Gynaecol 114:8–15 Franchini M, Lippi G, Franchi M (2007) The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage. Br J Obstet Gynaecol 114:8–15
2.
go back to reference Haynes J, Laffan M, Plaat F (2007) Use of recombinant activated factor VII in massive obstetric haemorrhage. Int J Obstet Anesth 16:40–49PubMedCrossRef Haynes J, Laffan M, Plaat F (2007) Use of recombinant activated factor VII in massive obstetric haemorrhage. Int J Obstet Anesth 16:40–49PubMedCrossRef
3.
go back to reference O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM (2006) Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 295:293–298PubMedCrossRef O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM (2006) Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 295:293–298PubMedCrossRef
4.
go back to reference Levi M, Peters M, Buller HR (2005) Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 33:883–890PubMedCrossRef Levi M, Peters M, Buller HR (2005) Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 33:883–890PubMedCrossRef
Metadata
Title
Recombinant human activated factor VII in postpartum hemorrhagic shock: the dark side
Authors
E. J. W. van Veen
W. E. Monteban-Kooistra
J. H. J. M. Meertens
J. J. M. Ligtenberg
J. E. Tulleken
J. G. Zijlstra
Publication date
01-01-2008
Publisher
Springer-Verlag
Published in
Intensive Care Medicine / Issue 1/2008
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-007-0810-0

Other articles of this Issue 1/2008

Intensive Care Medicine 1/2008 Go to the issue